+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy



Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy



American Journal of Cardiology 105(9): 1289-1296



Multiple randomized controlled trials (RCTs) have established the efficacy of statins for the prevention of cardiovascular disease. The benefits observed are often framed in terms of percentage reductions in low-density lipoprotein (LDL) cholesterol from baseline or percentage reductions between control and treatment groups, although epidemiologic data suggest that the absolute intergroup difference in LDL cholesterol (DeltaLDL(Control-Rx)) is the more informative measure. A systematic review of large-scale trials of statins versus placebo, usual care, or active (lower dose statin) control was conducted to calculate updated summary estimates of risk reduction in coronary artery disease and all-cause mortality. Meta-regression analysis was used to ascertain the relations of different LDL cholesterol metrics to outcomes. In 20 eligible RCTs, there were significant overall reductions for coronary artery disease (odds ratio 0.72, 95% confidence interval 0.67 to 0.78) and mortality (odds ratio 0.89, 95% confidence interval 0.84 to 0.94), but with substantial variability in trial results. DeltaLDL(Control-Rx) was the strongest determinant of coronary artery disease risk reduction, particularly after excluding active-comparator studies, and was independent of baseline LDL cholesterol. In contrast, baseline LDL cholesterol edged out DeltaLDL(Control-Rx) as the strongest determinant of mortality, but neither was significant after the exclusion of active-comparator studies. The exclusion of 3 RCTs involving distinct populations, however, rendered DeltaLDL(Control-Rx) the predominant determinant of mortality reduction. In conclusion, these findings underscore the primacy of absolute reductions in LDL cholesterol in the design and interpretation of RCTs of lipid-lowering therapies and in framing treatment recommendations on the basis of the proved coronary benefits of these drugs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055461483

Download citation: RISBibTeXText

PMID: 20403481

DOI: 10.1016/j.amjcard.2009.12.051


Related references

The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. American Journal of Cardiology 88(12-Supp-S1): 14-18, 2001

The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. American Journal of Cardiology 88(12a): 14n-18n, 2001

Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. Pharmacogenetics and Genomics 23(10): 518-525, 2013

Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease. Atherosclerosis 224(2): 454-456, 2012

Comparative meta-analysis of 6 statin and 9 non-statin coronary regression trials Evidence that cholesterol lowering is the key to outcomes. Circulation 94(8 Suppl. ): I579, 1996

Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis. Lipids in Health and Disease 14: 140, 2015

Does cholesterol lowering induce retardation of progression or even regression of coronary artery disease? a meta analysis of the angiographic coronary regression trials. European Heart Journal 13(ABSTR Suppl.): 161, 1992

Limit to benefits of large reductions in low-density lipoprotein cholesterol levels: use of fractional polynomials to assess the effect of low-density lipoprotein cholesterol level reduction in metaregression of large statin randomized trials. JAMA Internal Medicine 173(11): 1028-1029, 2013

Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. American Journal of Cardiology 104(10 Suppl): 3e-9e, 2009

Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy. Cardiovascular Revascularization Medicine 15(3): 131-136, 2014

Intensive LOwering of BlOod pressure and low-density lipoprotein ChOlesterol with statin theraPy (LOBOCOP) may improve neointimal formation after coronary stenting in patients with coronary artery disease. Coronary Artery Disease 20(4): 288-294, 2009

Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease: Frequency-Domain Optical Coherence Tomography Analysis. Jacc. Cardiovascular Imaging 11(11): 1721-1723, 2018

Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Annals of Internal Medicine 153(12): 800-808, 2010

Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study. Canadian Journal of Cardiology 26(2): 80-86, 2010

Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. American Journal of Cardiology 110(10): 1468-1476, 2012